Min-ran Li | Medicine and Dentistry | Women Researcher Award

Posted on by ScienceFather

Ms. Min-ran Li | Medicine and Dentistry | Women Researcher Award

Ms. Min-ran Li, The First Affiliated Hospital of Jinan University, China

Dr. Minran Li is the Chief Physician at the Division of Infectious Disease at The First Affiliated Hospital of Jinan University. He earned his M.D. in Internal Medicine from Peking University and has extensive expertise in infectious diseases, particularly nonalcoholic steatohepatitis (NASH) and chronic hepatitis B. His research focuses on discovering noninvasive biomarkers and the molecular mechanisms behind liver diseases. Dr. Li has published numerous articles and has been recognized as a Guangdong High-Level Personnel of Young Talents. 🏥📚

Publication Profile

Scopus

 

Education

Ms. Li holds an M.D. in Internal Medicine (Infectious Disease) from Beijing Peking University, a Master’s in Internal Medicine from Hebei Medical University, and a Bachelor’s in Clinical Medicine. This strong educational foundation has empowered her expertise in infectious diseases, particularly liver-related conditions like NASH (nonalcoholic steatohepatitis) and CHB (chronic hepatitis B).

Work Experience

Currently serving as Chief Physician in the Division of Infectious Diseases at the First Affiliated Hospital of Jinan University, Ms. Li has progressively taken on roles of increasing responsibility, including as Associate Chief Physician at The Fifth Hospital of Shijiazhuang. Her work centers on managing liver diseases and exploring innovative biomarkers.

Research Interests

Her research focuses on discovering noninvasive biomarkers for pathological features of NASH in combination with CHB. Her findings on the role of HIGD1A and fibrosis development in liver disease have been pivotal in identifying therapeutic targets, advancing the understanding of liver disease progression.

Awards and Recognitions

Her dedication has been recognized with honors such as the Guangdong High-Level Personnel of Young Talents Program and the Yangcheng Good Doctor Award, underscoring her excellence in medical research and practice.

Conclusion

Ms. Min-ran Li’s strong academic background, leadership in liver disease research, and national and international recognition make her a strong candidate for the Research for Women Researcher Award.

 

Publication Top Notes

  • Pan, Y. et al. (2024). Overexpression of LAG-3: a potential indicator of low immune function in tuberculosis. Frontiers in Cellular and Infection Microbiology, 14, 1410015. 🦠 (0 citations)
  • Li, M.-R. et al. (2024). The function role of HIGD1A in nonalcoholic steatohepatitis from chronic hepatitis B. Scandinavian Journal of Gastroenterology, 59(4), 445–455. 🥗 (0 citations)
  • Li, J.-Z. et al. (2023). Mechanism and Progress of Natural Products in the Treatment of NAFLD-Related Fibrosis. Molecules, 28(23), 7936. 🌿 (0 citations)
  • Li, M.-R. et al. (2023). Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population. Obesity Facts, 16(5), 427–434. 🍔 (1 citation)
  • Pan, Y. et al. (2023). Immune checkpoint inhibitors in cancer patients with COVID-19. Open Life Sciences, 18(1), 20220641. 💉 (1 citation)
  • Li, J.-Z. et al. (2022). Characteristics and treatment strategies for hepatocellular carcinoma caused by nonalcoholic fatty liver disease. Zhonghua gan zang bing za zhi, 30(12), 1392–1396. 🏥 (0 citations)
  • Yang, L. et al. (2022). Progress in research of lipogenesis inhibitors for treatment of nonalcoholic fatty liver disease. World Chinese Journal of Digestology, 30(16), 735–742. 🧬 (1 citation)
  • Li, J.-Z. et al. (2021). The identify role and molecular mechanism of the MALAT1/hsa-mir-20b-5p/TXNIP axis in liver inflammation caused by CHB in patients with chronic HBV infection complicated with NAFLD. Virus Research, 298, 198405. 🔬 (20 citations)
  • Zheng, X.-L. et al. (2021). Effect of optimizing oxygen therapy on multiple organ function and prognosis of patients with COVID-19. Chinese Journal of Pathophysiology, 37(5), 909–914. 🫁 (0 citations)
  • Li, M.-R. et al. (2020). Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutations. Journal of Viral Hepatitis, 27(10), 1044–1051. 🦠 (4 citations)

 

 

 

 

khadijeh kalanfarmanfarma | Health Professions Award | Best Researcher Award

Posted on by ScienceFather

Dr. khadijeh kalanfarmanfarma | Health Professions Award | Best Researcher Award

Dr. khadijeh kalanfarmanfarma, Kashan University of Medical Sciences, Kashan, Iran

Dr. Khadijeh Kalan Farmanfarma (born April 24, 1978) holds a PhD in Epidemiology and an M.Sc. in Health Education and Promotion. She has been recognized as a top researcher at both the national and university levels, notably at Zahedan University of Medical Sciences. Dr. Farmanfarma has contributed to over 20 high-impact publications, focusing on cancer epidemiology, metabolic syndrome, and public health. She is also a co-author of an eBook on the Renin-Angiotensin System and its role in diseases. Her research has earned her awards and recognition both nationally and internationally. 📚🌍🔬

 

Publication profile

Academic Background 🧠

Dr. Khadijeh Kalan Farmanfarma holds a PhD in Epidemiology and an M.Sc. in Health Education and Health Promotion. Her solid academic foundation is supported by multiple recognitions at the doctoral and master’s levels. Her focus on epidemiological research is crucial, particularly during global health challenges like COVID-19.

Research Contributions 📚

Dr. Farmanfarma has an impressive body of work, with more than 25 published research articles across Q1 to Q3 journals. Some highlights include:

COVID-19 Research: Her studies on the impact of COVID-19, especially on domestic violence and illness anxiety, show her commitment to addressing emerging public health issues.

Metabolic Syndrome & Cancer Epidemiology: Dr. Farmanfarma has published meta-analyses on metabolic syndrome and various cancers, which have gained significant attention in high-impact journals like Diabetes & Metabolic Syndrome: Clinical Research & Reviews (IF: 10.0, Q1).

Chronic Diseases & Breast Cancer Prevention: Her focus on chronic diseases and breast cancer prevention demonstrates her dedication to improving population health.

Recognitions 🏆

Dr. Farmanfarma’s accolades include being named the Top National Researcher and Top Researcher at Zahedan University of Medical Sciences multiple times, which speaks to her consistent excellence in research.

Publication Top Notes 

  • 📚 Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies – Cited by: 248 (2018)
  • 📚 Prevalence of metabolic syndrome in Iran: A meta-analysis of 69 studies – Cited by: 149 (2019)
  • 🧠 Brain cancer in the world: An epidemiological review – Cited by: 79 (2019)
  • 🎗️ Improving Breast Cancer Preventive Behavior among Female Medical Staff: Educational Intervention – Cited by: 59 (2014)
  • 📊 Epidemiologic study of gastric cancer in Iran: A systematic review – Cited by: 51 (2020)
  • 📈 Prevalence of type 2 diabetes in Middle-East: Systematic review & meta-analysis – Cited by: 47 (2020)
  • 🎗️ Effect of education on preventive behaviors of breast cancer in female teachers – Cited by: 35 (2014)
  • 🩺 Study of breast cancer knowledge, attitude, and preventive behaviors in Yazd, Iran – Cited by: 22 (2017)
  • 📊 Prevalence and trend of metabolic syndrome in South-East Iran – Cited by: 21 (2020)
  • 🧬 Testicular cancer in the world: An epidemiological review – Cited by: 20 (2018)

Conclusion 📝

With her extensive research output, recognitions, and focus on significant public health issues, Dr. Khadijeh Kalan Farmanfarma is a strong candidate for the Research for Best Researcher Award. Her diverse and impactful research contributions in epidemiology, particularly in chronic diseases and cancer, reflect a distinguished career deserving of recognition.